Clinical Trial Update: BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial updates exploring BKM120 in combination with Vemurafenib for BRAFV600E/K-mutant metastatic melanoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brafv600e-mutant Melanoma
• Melanoma

Drugs mentioned

• BKM120 (Buparlisib)
• Vemurafenib (vemurafenib)

Snippet

Sponsor: University of California, San Francisco | Conditions: BRAF Mutant Metastatic Melanoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-05-16